World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
73663
World Ranking
10636
National Ranking
382

Overview

Alba A. Brandes is affiliated with the Institute of Neurological Sciences in Italy. Their research spans multiple areas within medicine, biochemistry, genetics, and molecular biology, with a particular emphasis on oncology and cancer research.

Their scholarly work covers several specialized subfields, including:

  • Genetics
  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Molecular Biology

Brandes's research primarily focuses on topics related to:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Cancer Genomics and Diagnostics
  • Meningioma and schwannoma management
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Hypoxia, and Metabolism

Their frequent publication venues provide insight into the academic platforms where their work appears most often. These include:

  • Neuro-Oncology
  • The Lancet Oncology
  • Expert Review of Anticancer Therapy
  • Journal of Clinical Oncology
  • Diagnostics

Brandes has collaborated extensively with several coauthors, highlighting ongoing research partnerships with:

  • Enrico Franceschi
  • Vincenzo Di Nunno
  • Lidia Gatto
  • Martin J. van den Bent
  • Wolfgang Wick

Among Brandes's recent publications are significant works including:

  • "Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma" (2020), published in JAMA Oncology
  • "Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial" (2022), published in Neuro-Oncology
  • "Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study" (2021), published in The Lancet Oncology
  • "Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group" (2020), published in The Lancet Oncology
  • "Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas" (2021), published in CNS Oncology

Best Publications

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

    Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller

  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

    Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent

  • Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

    Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson

  • Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

    David A. Reardon;Alba A. Brandes;Antonio Omuro;Paul Mulholland

  • Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

    James R. Perry;Normand Laperriere;Christopher J. O'Callaghan;Alba A. Brandes

  • Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

    Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson

  • MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

    Alba A. Brandes;Enrico Franceschi;Alicia Tosoni;Valeria Blatt

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

    Michael Weller;Roger Stupp;Guido Reifenberger;Alba A. Brandes

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

    Andrés J. M. Ferreri;Michele Reni;Marco Foppoli;Maurizio Martelli

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

  • Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial

    René Olivier Mirimanoff;Thierry Gorlia;Warren Mason;Martin J. Van Den Bent

  • Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

    Thierry Gorlia;Martin J van den Bent;Monika E Hegi;Monika E Hegi;René O Mirimanoff

  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

    Brigitta G Baumert;Brigitta G Baumert;Monika E Hegi;Martin J van den Bent;Andreas von Deimling

  • Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

    Martin J van den Bent;Brigitta Baumert;Sara C Erridge;Michael A Vogelbaum;Michael A Vogelbaum

  • Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

    M J van den Bent;M J B Taphoorn;A A Brandes;Johan Menten

  • IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

    Martin J. van den Bent;Hendrikus J. Dubbink;Yannick Marie;Alba A. Brandes

Frequent Co-Authors

Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Roger Stupp
Roger Stupp Northwestern University
Michael Weller
Michael Weller University of Zurich
Johan M. Kros
Johan M. Kros Erasmus University Rotterdam
Michele Reni
Michele Reni Vita-Salute San Raffaele University
Anna K. Nowak
Anna K. Nowak University of Western Australia
Giovanni Tallini
Giovanni Tallini University of Bologna
Monika E. Hegi
Monika E. Hegi University of Lausanne
Khê Hoang-Xuan
Khê Hoang-Xuan Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school paths, several online degree options offer flexibility and career advancement. Many registered nurses look to increase their qualifications with adn to np programs online, allowing them to move from an associate-level nursing degree to becoming a nurse practitioner from anywhere.

If you are passionate about diet, wellness, and patient education, pursuing online degrees in nutrition can lead to rewarding roles in healthcare, public policy, or private practice.

For those aiming at healthcare administration, online mha programs cahme accredited ensure you receive a recognized credential, preparing you for leadership roles in hospitals or health systems.

Finally, working RNs seeking career progression can consider online rn-bsn programs without clinicals, allowing them to earn their BSN degree fully online without the need for on-site clinical hours.

These pathways demonstrate the broad educational possibilities available online, helping you chart a flexible and fulfilling healthcare career.

Best Scientists Citing Alba A. Brandes

Trending Scientists